46 results about "Sulfasalazine" patented technology

Methods for treating chronic wounds in a human are described by topically administering a dermatological composition comprising a TNF antagonist, a TACE inhibitor, a neutrophil antagonist, or a combination of a TNF antagonist and / or TACE inhibitor and a neutrophil antagonist. The TNF antagonist administered includes alefacept, efalizumab, etanercept, adalimumab, and onercept, while the neutrophil antagonist administered includes dapsone, colchicine, its analogs and prodrugs. The combination of TNF-antagonist and neutrophil antagonist administered includes sulfapyridine, sulfasalazine, mesalamine, and derivatives and prodrugs thereof. The topical compositions can be formulated to include the one or more of the antagonists in dissolved, semi-dissolved, and micro-particulate states.

In one embodiment, the present application discloses methods of treating diseases and disorders with sulfasalazine and pharmaceutical formulations of sulfasalazine where the bioavailability of the sulfasalazine is increased. In another embodiment, the present application also provides dosing regimens for treating neurodegenerative diseases and disorders with compositions comprising sulfasalazine.

A method is provided for inhibiting cellular uptake of cystine with a N-heterocyclic substituted salicylate for treatment such as sulfasalazine: Also provided we uses of a N-heterocyclic substituted Salicylate of cancer, for inhibition of cellular uptake of cystine, and for preparation of medicaments for the treatment of cancer or for inhibiting the cellular uptake of cystine. Preferably, the cancer is one which is dependent upon extracellular cystine or cysteine. Also provided are liposomal formulations of N-heterocyclic substituted salicylates.

The invention provides a human leukocyte antigen gene detection kit for screening skin drug adverse reaction caused by salazosulfapyridine, belongs to the technical field of biomedicine, and relates to a detection kit of human leukocyte antigen gene HLA-B*13:01, wherein the HLA-B*13:01 gene can be adopted as the marker gene of salazosulfapyridine-induced DRESS. According to the present invention, DNA is extracted from the peripheral blood of a patient, and the HLA-B*13:01 gene is detected by using the current method, such as PCR-SSO (sequence-specific oligonucleotide probe) method; and the HLA-B*13:01 gene detection kit of the present invention can be used for screening before the salazosulfapyridine use and screening the target drug for treatment of salazosulfapyridine-induced DRESS, wherein the screening before the salazosulfapyridine use can guide the clinical medication so as to reduce the occurrence of the salazosulfapyridine-induced DRESS, and the drug screening mainly act on the HLA-B*13:01 molecules in a targeting manner so as to block the interaction between the HLA-B*13:01 molecules and the salazosulfapyridine or the metabolites thereof in the pathogenesis.

The invention discloses an oral administration composition for delivering salicylic acid medicines to the intestinal tract. The composition comprises sustained release components, capsules and delayed release components, wherein the capsules are coated on the outer sides of the sustained release components and are coated by the delayed release components; the sustained release components comprise drug cores, organic acid layers and alkali-containing ethyecellulose layers; organic acids are coated on the outer side of the drug cores; the alkali-containing ethyecellulose is coated on the outer sides of the organic acids; the drug cores comprise sulfasalazine and / or 5-aminosalicylic acid; the capsules are prepared from gel, hydroxypropyl methyl cellulose or starch; and the delayed release components comprise polymers with enteric solubility. After the composition is subjected to oral administration during use, the medicine is delivered to the intestines, the drug release is controlled in the intestines to provide sustained release of the medicine, the salicylic acid medicines reach a to-be-treated area at enough concentration, and last for long time in the area, so that a local treatment effect is provided.

The present invention relates to a composition for inhibiting after-cataract including a hydrophilic sulfasalazine; a high content of hyaluronic acid; and a carrier containing an aqueous solution, and a method of preparing a composition for inhibiting after-cataract including the steps of adding hyaluronic acid powder to a hydrophilized sulfasalazine; and mixing the same with a specific condition.

The invention discloses a method for synthesizing doxepin hydrochloride by taking halomethyl o-toluate as a raw material. The method comprises the steps of sequentially carrying out substitution, hydrolysis, cyclization, nucleophilic addition, elimination reaction, nucleophilic substitution, nucleophilic substitution and neutral reaction on an initial raw material, namely halomethyl o-toluate with a wide source to obtain sulfasalazine; adding an organic lithium compound into an ether solvent in the seventh step, namely the nucleophilic substitution reaction step to ensure that the organic lithium compound and dimethylamine form ammonium and lithium salts; and next, carrying out alkylation reaction on the ammonium and lithium salts and halides to increase the yield of tertiary amine and furthermore finally ensure the yield and purity of doxepin hydrochloride.

The present invention relates to the technical field of sulfasalazine, specifically to a sulfasalazine synthesis process. The used technical scheme comprises that a compound represented by a formula I or a salt thereof and a compound represented by a formula II or a salt thereof are subjected to a reaction to prepare a compound represented by a formula III (the formulas I, II and III are defined in the specification), wherein R is hydrogen atom, alkyl, cycloalkyl, phenyl, and aralkyl, R2 is hydrogen and COR3, and R3 is alkyl, aryl, and aralkyl. With the technical scheme of the invention, the strict control of the reaction temperature is not required, and the production of the unstable diazonium salt can be avoided so as to avoid the production of the byproduct; and the product sulfasalazine can be directly precipitated through the simple treatment, the yield of the reaction is high, and the yield can achieve more than 90%.

A method of treating diabetic neuropathy in a subject includes administering to a subject having diabetes or at risk of diabetes a therapeutically effective amount of a pharmaceutical composition comprising at least one of sulfasalazine or a composition including 5-aminosalicyclic acid and sulfapyridine.

The invention discloses a preparation method for sulfasalazine. The preparation method comprises the steps of: S1, carrying out a diazotization reaction on sulfapyridine in an aqueous solution dissolved with hydrochloric acid and sodium nitrite to obtain diazonium salt; S2, carrying out a coupling reaction on the diazonium salt and salicylic acid in a sodium hydroxide aqueous solution to obtain a sulfasalazine crude product; and S3, purifying the sulfasalazine crude product. According to the preparation method disclosed by the invention, by taking sulfapyridine as an initial raw material, the diazotization reaction, the coupling reaction and purification are successively carried out to obtain the sulfasalazine. The diazotization reaction and the coupling reaction have a relatively high conversation rate and relatively few side reactions, so that the purity of the product is improved, and the yield is ensured. In addition, the sulfapyridine is easily available in source, so that the production cost is lowered, and the preparation method has relatively great industrial production value.

The present invention relates to a composition for treating an ocular inflammatory disease, comprising hydrophilic sulfasalazine and hyaluronic acid, and a preparation method therefor. Furthermore, the present invention relates to a method for treating an ocular inflammatory disease, which comprises administering, to an individual, a therapeutically effective amount of hydrophilic sulfasalazine and hyaluronic acid.

The invention discloses an application of a sharpleaf galangal fruit extract to preparation of medicines for treating inflammatory bowel diseases, belonging to the field of medicines. An extraction method of the sharpleaf galangal fruit extract comprises the following steps: extracting the sharpleaf galangal fruit extract; and preparing each part of the sharpleaf galangal fruit alcohol extract to obtain the liquid of each part of the sharpleaf galangal fruit alcohol extract. The sharpleaf galangal fruit extract has certain curative effects on inflammatory bowel diseases and has treatment effects similar to the treatment effects of sulfasalazine.

The present invention discloses a method for preparing doxepin hydrochloride using o-halogen methyl methyl benzoate as a raw material. In the method, o-halogen methyl methyl benzoate which is wide in source is used as a starting raw material, and sulfasalazine is obtained through substitution, hydrolysis, cyclization, nucleophilic addition, elimination reaction, nucleophilic substitution and neutralization reaction. The method comprises: during a nucleophilic substitution reaction obtained in the seventh step, using an organic lithium compound in an ether solution, so that the organic lithium compound and dimethylamine form an ammonium lithium salt (the formula is as shown in the description); then conducting an alkylation reaction on the ammonium lithium salt and a halide to improve the yield of tertiary amine, thereby ensuring the yield and purity of doxepin hydrochloride.

The invention relates to the technical field of sulfasal, in particular to a synthesis technology of environment-friendly sulfasalazine. A nitroso compound is condensed with ammonia to obtain the sulfasalazine. After adoption of the technical scheme, raw materials are cheap, easy to obtain and stable, and production of unstable diazonium salt is avoided, so that production of a byproduct is avoided; after adoption of the technical scheme, the product sulfasalazine can be directly separated out through simple treatment, so that the reaction yield is high.

The invention discloses a medicine for treating chronic colitis, which has the following medicine composition: Codonopsis pilosula, Atractylodes macrocephala, moxibustion licorice, angelica, white spoon, cinnamon, nutmeg, woody fragrance, myrobalan, millet shell, dried ginger , Compound Diphenoxylate Tablets, Sulfasalazine Tablets. It has the effects of invigorating the spleen and replenishing qi, invigorating qi and promoting blood circulation, nourishing qi and invigorating the middle, warming the middle and dispelling cold, reducing astringency and relieving diarrhea, reducing inflammation and relieving pain, levating the anus and stopping prolapse. The process is simple, the raw materials are easily obtained, the cost is low, the effect is quick, and the cure rate is high, so it is a medicine for treating chronic colitis worthy of popularization.

The present invention relates to a composition for treating osteoarthritis and a method for preparing the same, and more specifically, relates to a composition comprising hydrophilized sulfasalazine as an active ingredient and hyaluronic acid so as to enable effective treatment of osteoarthritis such as degenerative osteoarthritis by preventing joint wear in addition to symptom relief through intraarticular or local administration, and a method for preparing the same. When such a composition for osteoarthritis treatment is prepared by the preparation method according to the present invention, the dissolved state is maintained beyond a neutralization step after dissolution, preventing precipitation of sulfalazine by salting out occurring after neutralization, and thus a composition comprising high concentration of sulfasalazine can be prepared, and the composition prepared accordingly is highly effective in treating osteoarthritis, particularly degenerative osteoarthritis, through the intraarticular or local administration, since it comprises high concentration of sulfasalazine which had to be formulated at low concentration by conventional method due to poor solubility.

The present invention relates to a composition for inhibiting after-cataract including a hydrophilic sulfasalazine; a high content of hyaluronic acid; and a carrier containing an aqueous solution, and a method of preparing a composition for inhibiting after-cataract including the steps of adding hyaluronic acid powder to a hydrophilized sulfasalazine; and mixing the same with a specific condition.

In one embodiment, the present application discloses methods of treating diseases and disorders with sulfasalazine and pharmaceutical formulations of sulfasalazine where the bioavailability of the sulfasalazine is increased. In another embodiment, the present application also provides dosing regimens for treating neurodegenerative diseases and disorders with compositions comprising sulfasalazine.

The invention relates to the technical field of sulfasalazine, in particular to a synthesis process of salazosulfapyridine. Nitroso compound and ammonia are condensed to obtain salazosulfapyridine; byadopting the technical scheme provided by the invention, the reaction temperature does not need to be strictly controlled, and unstable diazonium salt can be avoided, so that the generation of by-products is avoided, and by utilizing the technical scheme provided by the invention, the product salazosulfapyridine can be directly separated out through simple treatment, and the reaction yield is high.

The invention relates to a sulfasalazine tablet preparation method. According to the method, a tablet preparation mold is adopted. The tablet preparation mold comprises an upper mold, a lower mold anda locating part. The upper mold is provided with a tablet preparation cavity which penetrates through the upper mold. The lower mold is provided with tablet preparation top columns. The tablet preparation top columns are respectively and fittingly inserted into the tablet preparation cavity. The locating part comprises a locating strip. The top end surface of the locating strip and the bottom endsurface of the locating strip abut against the upper mold and the lower mold respectively. The preparation method comprises the following steps: mixing up sulfasalazine powders with water, and stirring the mixture to prepare a sulfasalazine ointment; coating the sulfasalazine ointment on the tablet preparation mold to obtain the tablet preparation mold coated with the sulfasalazine ointment; drying the tablet preparation mold coated with the sulfasalazine ointment to obtain the tablet preparation mold loaded with a sulfasalazine tablet; driving the upper mold to get close to the lower mold soas to push out the sulfasalazine tablet by the tablet preparation top columns and obtain the sulfasalazine tablet. According to the invention, the sulfasalazine tablet preparation method is simple inprocess and the cost is reduced. The preparation method disclosed by the invention can be used for ensuring the weight stability of the sulfasalazine tablet.

The invention provides a human leukocyte antigen gene detection kit for screening skin drug adverse reaction caused by salazosulfapyridine, belongs to the technical field of biomedicine, and relates to a detection kit of human leukocyte antigen gene HLA-B*13:01, wherein the HLA-B*13:01 gene can be adopted as the marker gene of salazosulfapyridine-induced DRESS. According to the present invention, DNA is extracted from the peripheral blood of a patient, and the HLA-B*13:01 gene is detected by using the current method, such as PCR-SSO (sequence-specific oligonucleotide probe) method; and the HLA-B*13:01 gene detection kit of the present invention can be used for screening before the salazosulfapyridine use and screening the target drug for treatment of salazosulfapyridine-induced DRESS, wherein the screening before the salazosulfapyridine use can guide the clinical medication so as to reduce the occurrence of the salazosulfapyridine-induced DRESS, and the drug screening mainly act on the HLA-B*13:01 molecules in a targeting manner so as to block the interaction between the HLA-B*13:01 molecules and the salazosulfapyridine or the metabolites thereof in the pathogenesis.

The present invention relates to a composition for treating osteoarthritis and a method for preparing the same, and more specifically, relates to a composition comprising hydrophilized sulfasalazine as an active ingredient and hyaluronic acid so as to enable effective treatment of osteoarthritis such as degenerative osteoarthritis by preventing joint wear in addition to symptom relief through intraarticular or local administration, and a method for preparing the same. When such a composition for osteoarthritis treatment is prepared by the preparation method according to the present invention, the dissolved state is maintained beyond a neutralization step after dissolution, preventing precipitation of sulfalazine by salting out occurring after neutralization, and thus a composition comprising high concentration of sulfasalazine can be prepared, and the composition prepared accordingly is highly effective in treating osteoarthritis, particularly degenerative osteoarthritis, through the intraarticular or local administration, since it comprises high concentration of sulfasalazine which had to be formulated at low concentration by conventional method due to poor solubility.

The invention discloses a traditional Chinese and western medicine combination prescription for treating enteritis and a preparation method. The Chinese and western medicine combination prescription includes traditional Chinese medicine components and western medicine components, wherein the traditional Chinese medicine components comprise bighead atractylodes rhizome, astragalus membranaceus, radix codonopsis, poria cocos, coix seed, tangerine peel and antler gelatin, and the western medicine components comprise metronidazole, levofloxacin, domperidone, cisapride, sulfasalazine and norfloxacin. The preparation method includes the following steps of: step one, raw material selection; step two, raw material pretreatment; step three, preparation of the traditional Chinese medicine components; step four, preparation of the western medicine components, step 5, mixing of the traditional Chinese medicine components and the western medicine components and step 6, packaging and storage. The preparation method uses a combined process of traditional Chinese medicines and western medicines, shortcomings of the traditional Chinese medicines and shortcomings of western medicines are mutually complemented, the antler gelatin is used to reduce the side effects of some drugs, such as nausea, vomiting and bloating, moreover, the addition of tangerine peel can be used for regulating the middle warmer, stomach qi rising, nausea and vomiting can be treated, safety and reliability are achieved, the cure rate is high, relapse is not prone to occurring, adverse reactions do not exist, and both symptoms and root causes are addressed.

The present invention is directed to provide antitumor agent including water-soluble sulfasalazine as an active ingredient. Antitumor agents were obtained with, as the water-soluble sulfasalazine, a PEG-modified sulfasalazine represented by the following formula:wherein an average value of n is 4 or larger and 1136 or smaller.